Delivery Order SPE2DB22D3501-SPE2DB24FWE71

Award Date 7/8/24
Potential Completion Date 7/9/24
Potential Value $10K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic, a diabetes medication, and has a ceiling value of $19,494.89. The contract is a firm fixed-price delivery order with a period of performance through July 2024. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic, a diabetes medication. The contract has a ceiling value of $43,484.60 and a performance period through May 6, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical support vehicle for...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic, a diabetes medication, and has a ceiling value of $10,934.57. The contract has an ultimate completion date of March 10, 2025. This award is associated with a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the procurement of Ozempic, a medication used to treat diabetes, with a total ceiling value of $11,292.26 and a completion date of November 6, 2023. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ozempic, a medication used to treat diabetes, with a ceiling value of $1,460.70 and a period of performance through May 2, 2025. This award is associated with a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic, a diabetes medication. The contract has a ceiling value of $30,825.83 and a period of performance extending through May 12, 2025. The contract is a firm fixed-price, non-set-aside award, indicating open competition. AmerisourceBergen Drug Corp holds a large Indefinite Delivery Contract (IDC) with DLA Troop Support...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Ozempic, a medication used to treat diabetes, with a ceiling value of $2,282.50 and a period of performance through July 12, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company. The contract is for the supply of Ozempic, a prescription medication for the treatment of diabetes. The contract has a ceiling value of $1,468.02 and runs through July 12, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at up to...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Ozempic, a diabetes medication, with a ceiling value of $7,090.91 and a period of performance through April 2025. The contract is not set aside and is considered an open competition award. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00,...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic, a diabetes medication. The contract has a ceiling value of $15,741.58 and a period of performance through May 5, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical...
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB24FWE71
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic, a medication used to treat diabetes. The contract has a ceiling value of $10,089.20 and a period of performance ending on July 9, 2024. This award is under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award does not have a set-aside designation, indicating open competition.

Generated 5/17/25, 9:59 AM